Record-Breaking Price Performance
The stock of Gujarat Kidney & Super Speciality Ltd surged to an intraday high of Rs 183, closing near its 52-week peak of Rs 183.05, just 0.49% shy of this benchmark. This marks the highest valuation the stock has ever attained, underscoring strong investor confidence and sustained upward momentum. The day’s gain stood at 3.26%, outperforming the hospital sector by 2.39% and the broader Sensex index, which rose a modest 0.19% on the same day.
Notably, the stock has been on a positive trajectory for the past two consecutive days, delivering a cumulative return of 5.81% during this period. It is trading comfortably above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bullish technical trend that was confirmed on 16 September 2026 when the trend shifted from mildly bullish to outright bullish at a price of Rs 172.15.
Strong Relative Performance Over Multiple Timeframes
Gujarat Kidney & Super Speciality Ltd’s price appreciation has been remarkable across various time horizons. Over the past week, the stock gained 7.20%, while the Sensex declined by 0.43%. The one-month return stands at an impressive 19.40%, contrasting with the Sensex’s 3.60% loss. Over three months, the stock surged 42.88%, whereas the Sensex fell 3.81%. Year-to-date, the company’s shares have soared 78.20%, significantly outperforming the Sensex’s 12.63% decline.
While the stock’s one-year, three-year, five-year, and ten-year returns are recorded as zero, this is likely due to data availability constraints. However, the company’s recent performance clearly outpaces the broader market, especially in the current calendar year.
Financial Strength Underpinning the Rally
The company’s financial results have been a key driver behind this price surge. Gujarat Kidney & Super Speciality Ltd reported very positive quarterly results for June 2026, with net sales reaching Rs 34.29 crores, representing a 67.2% increase compared to the previous four-quarter average. Operating profit growth was even more pronounced, rising by 80.69%, while profit before tax (excluding other income) grew by 23.1% to Rs 6.27 crores. The company’s net profit after tax (PAT) hit a quarterly high of Rs 5.18 crores.
This strong earnings momentum has been consistent, with positive results declared for two consecutive quarters, reinforcing the company’s operational and financial stability.
Balance Sheet and Quality Metrics
Gujarat Kidney & Super Speciality Ltd maintains a low debt profile, with a Debt to EBITDA ratio of 1.08 times, indicating a strong ability to service its debt obligations. The company’s capital structure is rated excellent, and it boasts a robust return on capital employed (ROCE) of 26.45%, reflecting efficient utilisation of capital resources.
Management risk is assessed as average, while growth prospects are rated excellent. The company has no promoter share pledging, and institutional holdings stand at a modest 5.44%. Tax ratio is 20.82%, and the dividend payout ratio remains at zero, consistent with a focus on reinvestment and growth.
Valuation and Market Capitalisation
Despite the strong fundamentals and price appreciation, the stock carries a relatively high valuation. The price-to-earnings (P/E) ratio stands at 89 times trailing twelve months earnings, and the price-to-book value (P/BV) is 5.59 times. Enterprise value multiples are also elevated, with EV/EBITDA at 51.38 times and EV/EBIT at 62.23 times, reflecting market expectations for continued strong performance.
The company is classified as a micro-cap, indicating a smaller market capitalisation relative to larger hospital sector peers. This classification often entails higher volatility but also potential for significant price movements, as evidenced by recent gains.
Technical Indicators and Trading Activity
Technical analysis supports the bullish outlook, with key indicators such as MACD, Bollinger Bands, Dow Theory, and On-Balance Volume (OBV) signalling positive momentum on weekly and monthly charts. The relative strength index (RSI) shows a bearish reading, suggesting some caution in the short term, but overall trend indicators remain firmly positive.
Delivery volumes have increased notably, with a 1-month delivery change of 155.69% and a 1-day delivery change of 18.53% compared to the 5-day average, indicating heightened investor participation and confidence in the stock’s upward trajectory.
Summary of Key Metrics
• Current Price: Rs 183.50 (as of 18 Sep 2026, 09:42 AM)
• 52-Week High: Rs 183.05
• 52-Week Low: Rs 98.25
• Day’s High: Rs 183.00
• Market Cap Grade: Micro-cap
• Mojo Score: 70.0 (Buy Grade, upgraded from Hold on 16 Sep 2026)
• Debt to EBITDA: 1.08 times
• ROE: 6.1%
• P/E Ratio: 89x
• P/BV: 5.59x
• EV/EBITDA: 51.38x
• EV/EBIT: 62.23x
• Net Sales Growth (Quarterly): 67.2%
• PAT (Quarterly): Rs 5.18 crores (highest recorded)
• Consecutive Quarterly Positive Results: 2
Conclusion: A Milestone Marked by Strong Fundamentals and Market Recognition
The attainment of an all-time high price by Gujarat Kidney & Super Speciality Ltd on 18 September 2026 represents a significant milestone for the company and its shareholders. This achievement is underpinned by robust financial results, strong operational growth, and a solid balance sheet. The stock’s outperformance relative to the hospital sector and the broader market highlights its resilience and appeal within its micro-cap segment.
While valuation multiples remain elevated, reflecting market optimism, the company’s demonstrated ability to grow sales and profits, coupled with low leverage and strong capital efficiency, provides a sound foundation for its current market standing. The technical indicators and increased trading volumes further reinforce the positive sentiment surrounding the stock.
Overall, Gujarat Kidney & Super Speciality Ltd’s journey to this record price level is a testament to its financial discipline and growth trajectory within the hospital sector, marking it as a noteworthy performer in the current market environment.
